Surveillance E, End Results (SEER) Program (https://www.seer.cancer.gov). National Cancer Institute.: Cancer Stat Facts: Common Cancer Sites., 2022.

Surveillance E, End Results (SEER) Program (https://www.seer.cancer.gov). National Cancer Institute.: Cancer stat facts: prostate cancer., 2022.

(ACS) ACS: Cancer facts & Figures. Atlanta, Georgia, 2022.

Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Management of oligometastatic prostate cancer. Appl Radiat Oncol. 2020;9(3):6.

Article  PubMed  PubMed Central  Google Scholar 

Kinsey EN, Zhang T, Armstrong AJ. Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape. Cancer J. 2020;26:64–75.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network: Prostate Cancer (Version 4.2022).

• Hall ME, Huelster HL, Luckenbaugh AN, et al. Metastatic hormone-sensitive prostate cancer: current perspective on the evolving therapeutic landscape. Onco Targets Ther. 2020;13:3571–81. A succinct review of four chemotherapy, novel androgen receptor targeting agents in the treatment of mPCa.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Navrátil J, Poprach A, Lakomý R, et al. Oligometastatic prostate cancer. Klin Onkol. 2019;32:97–100.

Article  PubMed  Google Scholar 

Mahjoub S, Heidenreich A. Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. Transl Androl Urol. 2021;10:3167–75.

Article  PubMed  PubMed Central  Google Scholar 

Rao A, Vapiwala N, Schaeffer EM, et al. Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure? Am Soc Clin Oncol Educ Book. 2019:309–20.

Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15–25.

Article  CAS  PubMed  Google Scholar 

Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622–8.

Article  CAS  PubMed  Google Scholar 

Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.

PubMed  Google Scholar 

Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27–32.

Article  PubMed  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

Article  CAS  PubMed  Google Scholar 

Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.

Article  CAS  PubMed  Google Scholar 

Sprenkle PC, Mirabile G, Durak E, et al. The effect of argon gas pressure on ice ball size and rate of formation. J Endourol. 2010;24:1503–7.

Article  PubMed  Google Scholar 

Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95:1187–91.

Article  PubMed  Google Scholar 

Ukimura O, de Castro Abreu AL, Hung AJ, et al. Cryosurgery for clinical T3 prostate cancer. BJU Int. 2014;113:684–5.

Article  PubMed  Google Scholar 

Chin JL, Al-Zahrani AA, Autran-Gomez AM, et al. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c–T3b). J Urol. 2012;188:1170–5.

Article  PubMed  Google Scholar 

Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180:1993–2004.

Article  PubMed  Google Scholar 

Kwak K, Yu B, Lewandowski RJ, et al. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Theranostics. 2022;12:2175–204.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58:1–11.

Article  CAS  PubMed  Google Scholar 

Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol. 2015;194:378–85.

Article  PubMed  PubMed Central  Google Scholar 

Sheng MX, Wan LL, Liu CM, et al. Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: a retrospective analysis. Kaohsiung J Med Sci. 2017;33:609–15.

Article  PubMed  Google Scholar 

Sheng M, Guo S, Liu C. Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis. World J Surg Oncol. 2021;19:345.

Article  PubMed  PubMed Central  Google Scholar 

Wang N, Ye Y, Deng M, et al. Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study. Prostate Cancer Prostatic Dis. 2021;24:837–44.

Article  PubMed  PubMed Central  Google Scholar 

Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ross AE, Hurley PJ, Tran PT, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:184–93.

Article  CAS  PubMed  Google Scholar 

Li Y, Wang N, Zhao D, et al. Cytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer. Future Oncol. 2022;18:2373–80.

Article  CAS  PubMed  Google Scholar 

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10–8.

Article  PubMed  Google Scholar 

Daly T. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World J Urol. 2020;38:565–91.

Article  PubMed  Google Scholar 

Rogowski P, Roach M III, Schmidt-Hegemann NS, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16:50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol. 2021;205:22–9.

Article  PubMed  Google Scholar 

Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.

Article  PubMed  PubMed Central  Google Scholar 

Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695–707.

Article  CAS  PubMed  Google Scholar 

• Boevé LMS, Hulshof M, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial. Eur Urol. 2019;75:410–8. Outlines the results of the HORRAD trial investigating radiation therapy for patients with mPCa.

Article  PubMed  Google Scholar 

Aizawa R, Takayama K, Nakamura K, et al. Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: a combination of prostate-targeted treatment and metastasis-directed therapy. Int J Urol. 2021;28:749–55.

Article  CAS  PubMed  Google Scholar 

Inaba K, Tsuchida K, Kashihara T, et al. Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer. J Radiat Res. 2021;62:511–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dandapani SV, Wong J, Twardowski P. Review of radium-223 and metastatic castration-sensitive prostate cancer. Cancer Biother Radiopharm. 2020;35:490–6.

CAS  PubMed  Google Scholar 

•• Ranasinghe W, Chapin BF, Kim IY, et al. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020;125:792–800. This review outlines ongoing clinical trials investigating cytoreductive prostatectomy in mPCa and provides a concise explanation of expected results and perspective into trial components.

Article  CAS  PubMed